Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

ARCADIAN

FULL TITLE

A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination with Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer

 

SHORT TITLE

ARCADIAN: Atovaquone with Radical ChemorADIotherapy in locally Advanced NSCLC

 

The ARCADIAN trial has received Green Light approval from OCTRU and subsequently opened to recruitment at its first site in Oxford.

Funded by CRUK, ARCADIAN aims to investigate whether the drug atovaquone can be safely given to patients undergoing chemoradiotherapy for Non-Small Cell Lung Cancer (NSCLC).

Atovaquone has previously been shown to reduce tumour hypoxia, a state which can cause resistance to traditional cancer treatments. If the study shows that it is safe to administer atovaquone with chemoradiotherapy, further studies would be planned to assess the efficacy of this combination treatment.

 

Find out more on the Department of Oncology website: https://www.oncology.ox.ac.uk/about-us/overview/clinical-trials/clinical-trial-portfolio/arcadian

Similar stories

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

AVID-CC trial opens to recruitment!

OCTRU

The AVID-CC trial has received OCTRU Green Light approval and is now open to recruitment!

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research Trauma

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.

WHiTE Four trial results!

OCTRU

The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!

OCTRU

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!